Results from this study suggest that the benefit–risk profile of ponatinib is optimized by starting at a dose of 45 mg/day and reducing the dose to 15 mg/day upon achieving response (≤1% BCR-ABL1IS).
Brexucabtagene autoleucel produced durable, high rates of response in relapsed/refractory adult B-cell ALL with no unexpected safety signals.
Enasidenib shows promising efficacy and tolerability in patients with high-risk IDH2-mutated MDS.
Pooled analysis of clinical data suggests that venetoclax + azacitidine is both safe and efficacious in patients with secondary AML unfit for chemotherapy, including individuals with intermediate- or poor-risk cytogenetics.
Early-stage results with ivosidenib and venetoclax with or without azacitidine suggest a high CRc with a tolerable safety profile in patients with IDH1-mutated myeloid malignancies
Cytogenetic risk and MRD status identified as independent predictors of overall survival and relapse-free survival with oral azacytidine in this multivariate analysis.
Among patients with CR/CRi on venetoclax + azacitidine, achieving MRD <10-3 was associated with longer duration of response, event-free survival, and overall survival, regardless of when MRD negativity was attained.
In this head-to-head, randomized phase III trial, acalabrutinib proved to be noninferior to ibrutinib for PFS and demonstrated a more favorable safety profile, particularly regarding cardiovascular events.
In patients with previously untreated CLL/SLL, fixed-duration treatment of ibrutinib plus venetoclax resulted in deep and durable responses with high rates of treatment completion.
Addition of venetoclax to lenalidomide and rituximab in untreated MCL was well tolerated and showed early evidence of high response rates and undetectable MRD.
Tisagenlecleucel, a CD19 targeted CAR T-cell therapy, demonstrated a high overall response rate with durable responses in adult patients with relapsed/refractory follicular lymphoma.
After a median follow-up of approximately 4 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS and consistent safety profiles vs chemoimmunotherapy in adults with treatment-naive CLL.
Based on longer follow-up data, epcoritamab continues to show a manageable safety profile, with low-grade CRS, along with high response rates at doses ranging from 0.75-60 mg across disease histologies.
Results of this subgroup analysis show that KRd-ASCT, as compared with KRd12, and KR maintenance, as compared with R maintenance, prolonged PFS across all cytogenetic risk groups except patients with amp(1q).
In patients with newly diagnosed MM, compared with observation, daratumumab maintenance significantly improved PFS and depth of response following induction/consolidation therapy.
Subcutaneous elranatamab, a BCMA-/CD3-targeted bispecific antibody, had a manageable safety profile and encouraging activity in relapsed/refractory multiple myeloma as reported in the MagnetisMM-1 phase I trial.
In patients with R/R MM, updated results with idecabtagene vicleucel suggest high response rates and durable responses, regardless of the number of prior therapies.
Updated results from ICARIA-MM confirm significant PFS benefit and show improvement in time to next therapy with addition of isatuximab to pomalidomide/low-dose dexamethasone in relapsed/refractory myeloma.
In heavily pretreated patients with relapsed/refractory multiple myeloma, PFS was comparable with ixazomib + dexamethasone and pomalidomide + dexamethasone as shown in a randomized phase II trial.
Addition of isatuximab to carfilzomib/dexamethasone improved PFS in patients with difficult-to-treat R/R MM, including older patients, patients with MM refractory to previous therapy, and those with high-risk cytogenetics.
Post-hoc analysis of the DREAMM-2 findings suggest that BCVA changes and patient-reported ocular symptoms are concordant with corneal exam findings after belantamab mafodotin treatment in the majority of cases.